Posts Tagged ‘Cymbalta’

4 Creepy Ways Big Pharma Peddles its Drugs

Tuesday, January 10th, 2012

Big Pharma uses ads that sow hypochondria, raise health fears and sell diseases to adults and their children.

Alternet
By Martha Rosenberg
January 9, 2012

It’s no secret that advertising works. Big Pharma wouldn’t spend over $4 billion a year on direct-to-consumer advertising if it didn’t mean massive profits.

What is more unknown is why drug ads that sow hypochondria, raise health fears and “sell” diseases are often the most common–and effective–even when the drugs themselves are of questionable safety.

The nation’s fourth most frequent drug ads in 2009 for were Cymbalta, making Eli Lilly $3.1 billion in one year, despite the antidepressant’s links to liver problems and suicide. Pfizer spent $157 million advertising Lyrica for fibromyalgia in 2009, despite the seizure pill’s links to life-threatening allergic reactions. The same year, it spent $107 million advertising the antidepressant Pristiq, even though it also had links to liver problems.

So, how does Pharma dupe us into using unsafe drugs? Today’s drug ads, targeted directly to consumers since 1999, seem like they sell diseases and often cast women, children, the elderly and mentally ill in a bad light. But a quick look at ads before direct-to-consumer advertising (DTC) in medical journals shows that drug ads have always done so. It’s just that patients didn’t used to see them.

Here are some of Pharma’s most offensive ad campaigns, then and now.

1. You’re Sicker Than You Think

When psychiatric drugs first became popular for use in the general population, in the late 1960s, everyday personality problems became imbued with psychiatric labels. “Lady, your anxiety is showing (over a coexisting depression),” says a 1970 ad, showing an older, wrinkly woman in a bouffant wig with gigantic sunglasses and garish jewelry. “On the visible level, this middle-aged patient dresses to look too young, exhibits a tense, continuous smile and may have bitten nails or overplucked eyebrows,” says the ad copy. “What doesn’t show as clearly is the coexisting depression.”

The ad, both sexist and ageist, suggests the woman needs the antidepressant and tranquillizer Triavil.

Another ad from 1968 shows a bored, upper-middle-class couple whose hauteur is also said to really be depression. “Do you have patients who try to hide frustration behind conformity?” says the ad for the antidepressant Aventyl HCl.

You’d think such demeaning ads would vanish with DTC advertising because people would be offended. But You’re Sicker-Than-You-Think ads are alive and well since DTC advertising and even flowering.

A three-page consumer ad in the late 2000s similarly conveys that everyday psychological traits could actually be dire mental problems that require medication. If you are “talking too fast,” “spending out of control,” “sleeping less,” “flying off the handle” and “buying things you don’t need,” you could be suffering from bipolar disorder said the ads, which appeared in magazines like People. And here you thought it was the coffee. Accompanying photos of a woman screaming into a phone and contorting her face are so extreme they could come out of the movie Halloween Part II, if the woman were holding a knife.

Click to enlarge image

Psychiatric drugs are not just advertised for everyday personality problems. Pharma is pushing them for everyday pain conditions. Eli Lilly’s original depression campaign for the antidepressant Cymbalta, “Depression Hurts,” seems to anticipate its subsequent approval for pain conditions including back problems. Now ads tout Cymbalta as a “non-narcotic, once daily analgesic FDA approved for three indications across four different chronic pain conditions,” as if it does not have severe controversial psychiatric risks including the suicide of volunteers who tested it.

And seizure and epilepsy drugs, known for major allergic and psychiatric reactions, are also becoming pain franchises. “What’s causing your chronic widespread muscle pain?” asks an ad for the seizure and epilepsy drug Lyrica. “The answer may be overactive nerves,” says the ad, even though “widespread muscle pain” and “over-active nerves,” are not mentioned in the approved labeling for Lyrica, says pharmaceutical reporter John Mack. The military spent $35 million on seizure and epilepsy drugs in 2009 alone, including for migraines, headaches and pain.

And speaking of overkill, ads for genetically engineered injected drugs like Humira, approved to treat serious diseases like Crohn’s disease, psoriatic arthritis and chronic plaque psoriasis look like they are designed to sell beer or beauty treatments, not immune suppressing drugs that invite cancers and lethal infections.

DTC ads don’t just escalate everyday problems into psychiatric problems, they also escalate real psychiatric problems into irresponsible, sensationalistic stereotypes. Ads for the best-selling antipsychotic Risperdal, widely used in children, and in soldiers with PTSD, suggest that people with mental illness have hallucinatory fears about “boiling rain” and “dog women.” The “dog woman” ad, showing a half-dog, half-woman crouched on her elbows, her eyes blackened, furthers the sensationalizing of mental illness with the tagline, “Because relapses are a living nightmare.”

2. Your Kid Is Sick 

DTC ads don’t just convince people they’re in need of new drugs, but also that their kids may be, too. And it’s been going on for decades.

Long before Pharma convinced parents, teachers and clinicians that millions of US kids had attention deficit hyperactivity disorder (ADHD), kids were said to suffer from “minimal brain dysfunction” (MBD) and “hyperkinesis,” two conditions that were essentially the same as ADHD. In fact, so many kids had MBD by 1976 that an ad for the drug Cylert hailed the “Importance of single daily dose to the child, the parents and the teacher,” because kids wouldn’t have to be singled out anymore at pill time at school. (ADHD has been so huckstered, a YMCA ad spoofs it with the headline, “Before video games, before Facebook, before Ritalin, there was basketball.”)

Yet neither Cylert–whose approval the FDA withdrew in 2005 because of liver failure and deaths–or the current ADHD drugs are safe. In 2009, researchers reported that kids are more likely to die sudden deaths while taking them and the American Heart Association recommends electrocardiograms (ECGs) before kids take them. And yet, combined sales of ADHD drugs continue to grow from $4.05 billion to $7.42 billion in 2010.

Thirty years ago, it certainly looked like kids were being overmedicated. They were given the antipsychotic Thorazine for their “hyperactivity,” “hostility,” sleep problems and even for vomiting. Picky eaters and kids who wet the bed were given tranquillizers. Kids with tics, stuttering and school phobia were given the tranquillizer Miltown.

Click to enlarge image

But today, ads promoting drugs for kids continue, and now they are aimed at parents. Sometimes, it’s hard to tell the difference between ads for drugs or ads for sugary cereals! Pharma tells moms to give their kids the bubble gum-flavored ADHD med, LiquADD and the grape-flavored ADHD med, Methylin. The latter campaign, to parents, is “Give ‘em the GRAPE!”

DTC advertising has also convinced parents their kids suffer from GERD (gastroesophageal reflux disease) otherwise known as acid reflux disease, which was barely a disease in adults much less kids, before consumer advertising. “GERD Can Be a Big Problem for Little Kids,” say award-winning ads for Prevacid, which won a “RX Club” Silver award in 2004. In Europe, kids are treated for another “adult disease” and given chewable Liptitor to lower their cholesterol.

Some of Pharma’s most aggressive advertising has been designed to convince parents their children’s minor sniffles or wheezing are imminent asthma and require immediate and expensive drugs. To make the asthma drug Singulair (which also comes in a yummy chewable), the seventh most popular drug in 2010, Merck inked partnerships with the American Academy of Pediatrics and Scholastic, both of which parents consider neutral organizations and not Pharma mouthpieces. Merck also partnered with Olympic gold-medalist swimmer Peter Vanderkaay and NBA kid clubs to sell the asthma drug.

“A kid who’s got what your kid’s got is out doing what your kid’s not,” says one Singulair ad campaign. “Find out how you can help your child breathe a little easier.”

If Singulair were not harmful, the huckstering would simply be a case of wasting money and overmedicating kids. But Singulair has been linked to both pediatric suicide and to emotional, behavioral and ADHD-like symptoms in kids, the latter likely inspiring parents to give their kids “the grape.”

Of course, another kid-targeted campaign is for the vaccine against the sexually transmitted Papillomavirus or HPV, immortalized by Gov. Rick Perry and Rep. Michele Bachmann in hot exchanges this fall. Many object to the sexualizing of 9-year-olds, to government lining Pharma’s pockets by promoting the vaccine (including overseas) and to the risks of the vaccines themselves. But the ads for Gardasil and Cervarix are also offensive.

Last spring, poster-sized ads for Gardasil on Chicago’s commuter trains pretended to sell real estate in sought-after neighborhoods. A closer look revealed descriptions of women in those neighborhoods who thought they didn’t need the HPV vaccine but did, positioning HPV not only as a general risk to the population, like flu, rather than an STD but as “hip.”

HPV vaccine ads got even cooler when GSK rolled out Cervarix extravaganza TV ads and its “armed against cervical cancer” campaign with an Angelina Jolie-like model displaying a skinny arm with a Cervarix tattoo.

3. Be Like Me, and Can Your Beer Do This?

Click to enlarge image

Prescription drugs may affect health, but they are still consumer products sold with the same marketing principles as toothpaste or beer. In fact, the wacky, “Can Your Beer Do This?” Miller Lite campaign of the 1990s, came back to life to sell the antidepressant Wellbutrin XR. In a glossy, color magazine ad, a young man rows his girlfriend on a scenic lake and lists the benefits of his Wellbutrin XR. “Can your medicine do all that?” he asks.

What does it say about the success of DTC advertising that people are assumed to have an antidepressant?

Experiential ads also sell prescription drugs like vintage ads for the “Kodak Moment,” “Maalox Moment” and the old cigarette ads for the “L&M Moment” did. “Lunesta Sleep. Have You Tried it?” asks a 2007 ad in Parade magazine, elevating the experience to something akin to “designer sleep.”

Click to enlarge image

And just as celebrities move other consumer products, they have been deployed to sell prescription drugs. TV personality Joan Lunden and former baseball star Mike Piazza stumped for the allergy pill Claritin, ice skater Dorothy Hamill and track star Bruce Jenner for the pain pill Vioxx, and Sen. Bob Dole for Viagra. NASCAR figure Bobby Labonte also endorsed the antidepressant Wellbutrin XL in 2004. Yes, his medicine could “do all that.”

But there has been a problem with celebrity drug endorsements, unlike product endorsements in which a celebrity like Tiger Woods or Martha Stewart could taint a product, a prescription drug can taint a celebrity! Did Dorothy Hamill know that Vioxx doubled the risk of heart attacks in users when she stumped for it? Did the model Lauren Hutton know that hormone replacement therapy causes a 26 percent higher incidence of breast cancer, a 29 percent increase in heart attacks, a 41 percent increase in strokes, and a doubling of the rate of blood clots when she shilled for it? Does actress Sally Field know that bone drugs like Boniva are linked to esophageal cancer, jaw bone death and the very fractures they are supposed to prevent as she pushes them?

Of course, good product marketing includes public relations. When Pharma sells a disease with no mention of the drug it is really selling, it’s called “unbranded” advertising. Since DTC advertising, Pharma has invaded public service announcements (PSAs) that TV and radio stations confer for free, pretending their take-a-drug messages serve the public good, like messages to change smoke detector batteries or put kids in car seats.

One such “educational” “awareness” campaign called “Depression Is Real” saturated the radio air waves in 2011, funded by the National Alliance on Mental Illness, which was investigated by Congress for its Pharma funding from Wyeth, part of Pfizer, and other groups. The high-budget ads, running for free, compare depression to diabetes because it doesn’t go away and to cancer because it can be fatal.

4. One Kind of Ad You Won’t See Anymore

Animal research at drug companies and the National Institutes of Health is a great scientific iceberg of which people only see a tip. In drug development, millions of animals die to prove a drug’s “safety.” At academic and medical centers, animal study grants from NIH provide millions to researchers and labs.

As sentiment grows against animal experiments and the government’s gigantic National Primate Research Centers (new rules will limit the use of chimpanzees), the research is downplayed and even hidden. But there was a time when Pharma actually flaunted animal research.

Click to enlarge image

“More than a decade of animal research on various animal species has suggested that Librium (chlordiazepozxide HCI) exerts its principal effects on certain key areas of the limbic system,” says an ad from the 1970s, showing three monkeys crouching and dangling in cages as assorted experiments are conducted.

An ad for the diet pill Pre-Sate is even worse. It says, “one of the most sophisticated comparative animal studies ever conducted demonstrates direct action on the satiety centers,” and shows five photos of cats in experiments. One shows a life-size white cat looking at the camera with a chain around its neck and invasive instrumentation embedded in its skull.

Today’s consumers, it seems, wouldn’t tolerate ads like these. (Or the experiments behind them.) Why do they tolerate derisive ads about “dog women” and ploys to market pharmaceuticals to kids as if it were candy?

http://www.alternet.org/drugs/153677/4_creepy_ways_big_pharma_peddles_its_drugs?page=entire

« Return to news items


Share

Selling Depression—Adding New Spin and Urgency to Depression Drug Sales

Tuesday, June 21st, 2011

CounterPunch – June 19 Edition

by Martha Rosenberg

The discovery that many people with life problem or occasional bad moods would willingly dose themselves with antidepressants sailed the drug industry through the 2000s. A good chunk of the $4.5 billion a year direct-to-consumer advertising has been devoted to convincing people they don’t have problems with their job, the economy and their family, they have depression. Especially because depression can’t be diagnosed from a blood test.

Unfortunately, three things dried up the depression gravy train for the drug industry. Blockbusters went off patent and generics took off, antidepressants were linked with gory and unpredictable violence, especially in young users and — they didn’t even work, according to medical articles!

That’s when the drug industry began debuting the concept of “treatment resistant depression.” It wasn’t that their drugs didn’t work (or you didn’t have depression in the first place), you had “treatment resistant depression.” Your first expensive and dangerous drug needed to be coupled with more expensive and dangerous drugs because monotherapy, one drug alone, wasn’t doing the trick!

You’ve got to admire the drug industry’s audacity with this upsell strategy. Adding drugs to your treatment resistant depression triples its take, patients don’t know which drug is working so they’ll take all of them and the defective drugs are exonerated! (Because the problem is you.)

Now the drug industry has a new whisper campaign to keep the antidepressant boat afloat. Your depression is “progressive.”

Once upon a time, when depression was neither seasonal, atypical, bipolar or treatment resistant, it was considered to be a self-limiting disease. In fact, just about the only good thing you could say about depression was it wouldn’t last forever.

But now, the drug industry is giving depression the don’t-wait scare treatment like coronary events (statins), asthma attacks (“controller” drugs) and thinning bones (Sally Field). If you don’t hurry and take medication, your depression will get worse!

“Depressive episodes become more easily triggered over time,” floats an article on the physician Web site Medscape (flanked by ads for the antidepressant Pristiq.) “As the number of major depressive episodes increase, the risk for subsequent episodes is predicted more from the number of prior episodes and less from the occurrence of a recent life stress.” The article, unabashedly titled “Neurobiology of Depression: Major Depressive Disorder as a Progressive Illness,” is written by Vladimir Maletic who happens to have served on Eli Lilly’s Speaker’s Bureau, says the disclosure information, and whose co-authors are each employees and/or Lilly shareholders.

On WebMD, a sister site to Medscape, the depression sell is even less subtle. An article called Recognizing the Symptoms of Depression, smothered with five ads for the Eli Lilly antidepressant, Cymbalta, submits, “Most of us know about the emotional symptoms of depression. But you may not know that depression can be associated with many physical symptoms, too.”

Depression may masquerade as headaches, insomnia, fatigue, backache, dizziness, lightheadedness or appetite problems mongers the article. “You might feel queasy or nauseous. You might have diarrhea or become chronically constipated.” And here, you thought it was something you ate!

The danger with these symptoms says the article is that you would fail to diagnose yourself as suffering from a psychiatric problem and buy an over-the-counter drug like a normal person. “Because these symptoms occur with many conditions, many depressed people never get help, because they don’t know that their physical symptoms might be caused by depression. A lot of doctors miss the symptoms, too.”

But when head and backaches aren’t labeled as depression, the drug industry make no money and insurance rates could stop climbing from over-treatment with unnecessary, expensive and dangerous psychoactive drugs!

To prevent such goring of marketshare, the article (whose content was “selected and controlled by WebMD’s editorial staff and is funded by Lilly USA,” an original WebMD financial partner according to the Washington Post) counsels worry about physical symptoms. “Don’t assume they’ll go away on their own.” Symptoms may “need additional treatment” and “some antidepressants, such as Cymbalta and Effexor, may help with chronic pain, too.”

Before direct-to-consumer advertising, the health care system was devoted to preventing over-treatment and assuring patients they were probably okay. Who remembers “Take two aspirin and call me in the morning”? Now patients are assured they probably aren’t okay but probably have a progressive disease. Luckily their disease can be treated with progressive prescriptions from pharma.

http://www.counterpunch.org/rosenberg06172011.html

« Return to news items


Share

Panel to Examine Murder and Suicide Associated With Antidepressants

Tuesday, March 22nd, 2011

The Huffington Post, March 22, 2011
by Dr. Peter Breggin

Click image to visit the Psychiatric Drug Database

On Saturday morning April 9th of this year, a panel discussion will be held for the public and professionals on the theme of “Psychiatric Drug Tragedies: Personal, Legal and Medical Perspectives.”

The two-hour presentation focuses on suicide and murder potentially caused by antidepressant medications. It is part of the international Empathic Therapy Conference put on by the Center for the Study of Empathic Therapy, Education & Living (April 8-10, 2011 in Syracuse, New York).

The panel will present a unique examination of an antidepressant-related suicide from three perspectives: Mathy Downing, the mother of a twelve-old-child who committed suicide; Karl Protil, the lawyer in her case, which was settled without any admission of negligence; and myself as the medical expert in the case. Mathy will be accompanied by her surviving daughter. Other family members will tell the stories of two more children who committed suicide, a father who committed suicide, and a husband who murdered his two young children–all while taking prescribed antidepressants.

A great deal is now known about suicide and violence in association with the newer antidepressants such as Prozac (fluoxetine), Paxil (paroxetine), Zoloft (sertraline), Luvox (fluvoxamine), Celexa (escitalopram), Lexapro (escitalopram), Cymbalta (duloxetine), Effexor (venlavaxine), Pristiq desvenlafaxine), and Wellbutrin (bupropion).

The FDA has imposed a Black Box on all antidepressant labels that warns against the risk of suicidal behavior in children, youth and young adults. Click here to find the example of Prozac’s official prescribing information. More importantly and more broadly, the new labels also warn about the risk of aggression, hostility, mania, and an overall worsening of the individual’s mental condition, for all ages. The new FDA-approved labels also include a Medication Guide, which the FDA urges prescribers to give to patients and their families. Originally intended for children taking antidepressants, it now has no age limitation and pertains to all ages. The Medication Guide warns patients and their families to be aware of the possibility of suicidal and violent behavior, mania, and a long litany of other dangerous mental abnormalities.

The new FDA-approved antidepressant labels confirm that the risks are highest at the start of medication therapy or during changes in dose, either up or down. To a great extent, the labels read like my prior publications, one of which was given by the FDA to its outside expert committee that recommended the changes to the labels.

Unfortunately, many psychiatrists, internists, family doctors, nurse practitioners and other professionals continue to prescribe these medications, too often without providing adequate information to the patient and the family. As a result, I was asked to write about the implications of these new labels for the most widely read psychiatric journal for primary care prescribers. The panel at the Empathic Therapy Conference, the first of its kind, will explore these tragedies and put a human face on them through the presence and presentations of surviving family members.

Other aspects of the conference will describe empathic approaches to helping a wide variety of emotional conditions and problems in children and adults. Speakers will bring unique and inspiring approaches to children and adults given psychiatric diagnoses, ordinary folks who are suffering from stress, street people overcome by psychosis, military personnel recovering from PTSD and head injuries, and elderly victims of dementia. Professionals and the general public are welcome at the Empathic Therapy Conference in Syracuse, New York, April 8-10, 2011. Continuing education credits (CEs) for 29.5 hours are available.

Peter R. Breggin, MD is a psychiatrist in private practice in Ithaca, New York, and the author of dozens of scientific articles and more than twenty books including Toxic Psychiatry: Why Therapy, Empathy and Love Must Replace the Drugs, Electroshock and Biochemical Theories of the “New” Psychiatry, as well as his newest book, Medication Madness. The Empathic Therapy Conference brings together more than forty presenters and a diverse audience from around the world. Professionals and nonprofessionals are welcome. Learn about the conference at http://www.empathictherapy.org.

« Return to news items


Share

US Soldiers’ Suicides Caused by Prescription Drugs?

Monday, November 1st, 2010

The Epoch Times, November 1, 2010

by Martha Rosenberg

The suicide rate among U.S. troops is astonishing.

In 2009 there were 239 suicides within the Army, including the Reserves, 160 active duty suicides, 146 active duty deaths from drug overdoses and high-risk behavior, and 1,713 suicide attempts, says the Army’s suicide report released in July.

More troops are dying from their own hands than in combat, says the Army report, titled “Health Promotion, Risk Reduction, and Suicide Prevention.” Thirty-six percent of the suicides were among troops who were never deployed.

Also astonishing is the psychoactive prescription drug rate among active duty-aged troops, aged 18 to 34, which is up 85 percent since 2003, according to the military health plan, Tricare. Including family prescriptions, since 2001, 73,103 prescriptions for Zoloft have been dispensed, 38,199 for Prozac, 17,830 for Paxil, and 12,047 for Cymbalta. All of the drugs carry a suicide-warning label.

In addition to the spike in SSRI antidepressant prescriptions, prescriptions for the anticonvulsants Topamax and Neurontin rose 56 percent in the same group since 2005, says Navy Times. The FDA warned last year that taking these drugs doubles suicidal thinking.

In fact, 4,994 troops at Fort Bragg, N.C., are on antidepressants right now, says the Fayetteville Observer. Six hundred and sixty-four are on an antipsychotic and “many soldiers take more than one type of medication.”

Troops may also be taking Chantix, an antismoking drug so linked to violence and self-harm that Secretary of Veterans Affairs James Peake was forced to defend its use before the House Committee on Veterans Affairs in 2008 even in drug trials. Related Articles

“If you know the drug induces suicidal thoughts,” an unappeased committee chair Bob Filner, D-Calif., asked Rep. Filner, “Why don’t you just stop [prescribing it]?”

The FDA says that even widely prescribed asthma drugs like Singulair and Advair are linked to suicide and have been cited in young people’s deaths.

Who knows what happens when the drugs are mixed with mood stabilizers, insomnia meds, pain pills, anti-anxiety drugs, and antipsychotic pills? These drug combinations have never been tested for safety.

Links between suicide and even murder-suicide and selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) antidepressants have been long recognized.

Traci Johnson, a healthy 19-year-old with no mental problems, hung herself during Lilly trials of Cymbalta in the drugmaker’s own clinic in 2004. Columbine shooter Eric Harris had reportedly just switched from Zoloft to Luvox.

Red Lake shooter Jeff Weise who killed 10 on a Minnesota Native American reservation in 2005 had just upped his Prozac dose. And the Virginia Tech shooter, Cho Seung-Hui, was also on psychoactive medications, say news reports.

Even though Americans have doubled their antidepressants since 1999 so that 10 percent of the population or 27 million now take them, suicides have climbed by 5 percent since 1999 and 16 percent in middle-aged adults, says an article in the American Journal of Preventive Medicine in 2008.

In fact, the high percentage of civilian suicides on psychoactive drugs is probably the clearest indication that military life is not the only cause of the shocking troop suicides.

In September alone, there were 18 civilian suicides, 11 murders, 2 murder-suicides, and other violence linked to people who were using or had used antidepressants, according to published reports. (Ssristories.com/index.php?sort=what&p=recent)

A 54-year-old patient with a breathing tube and an oxygen tank and no previous criminal record held up a bank in Mobile, Ala. She had gone off her antidepressants.

An enraged man in Australia, also off his antidepressants, chased his mailman and threatened to cut his throat for bringing him junk mail.

A 58-year-old Amarillo, Texas, man with no criminal history tried to abduct three people, killing an Oklahoma grandmother in the process. He had “an antidepressant in his blood,” said police.

Also in the 30-day period, a 60-year-old grandmother in Seattle killed three family members and herself; a disc jockey in Bristol, U.K., set himself on fire; and a man in Exeter, U.K., was found to have stabbed himself in the heart. All were on antidepressants.

Finally, in the month of September, legal proceedings began against two mothers and a father charged with killing their own children.

Over 4,000 published reports of violent and bizarre behavior of people affected by antidepressants on the Web archive ssristories.com reveal the same out-of-character violence and self-harm in civilians that is currently seen in the military.

Twenty people set themselves on fire. Ten bit their victims (including a biter who was sleepwalking and a woman, on Prozac, who bit her 87-year-old mother into a critical condition.) Three men in the 70s and 80s attacked their wives with hammers.

Many stabbed their victims obsessively—one even stabbed furniture after killing his wife—and 14 parents drowned their children, a crime seldom heard of before the 2001 Andrea Yates case. Yates, who drowned her five children, was on the antidepressant Effexor, which manufacturer Wyeth (now Pfizer) “issued no public warning” about [the possibility of violent behavior], says the Associated Press.

Then there was the North Carolina pilot on Zoloft who sang “I’m going down for the last time” into the cockpit voice recorder before he crashed his plane in June. And the mayor of Coppell, Texas, Jayne Peters, who killed herself and her daughter in July over the grief of losing her husband. Police found antidepressants at the home.

Such murder-suicides committed by women used to be rare, says Betty Henderson the ssristories.com moderator and researcher. “Before the SSRI antidepressants, women committed 5 percent of the murder-suicides, and now they account for almost 15 percent of this type of violence,” she said in an interview.

Antidepressants are also causing women to become sexual predators, says Henderson. “There have been more than a dozen recent cases of women school teachers molesting their young students under the influence or withdrawal of antidepressants. Who heard of this type of sexual aberration before the antidepressant craze?”

Why don’t doctors and media outlets publicize the names of these volatile drugs?

“It’s a good question,” said Dr. Gary Kohls, a Minnesota family practitioner, in an op-ed written after Iraq veteran Matthew Magdzas killed his pregnant wife, their 13-month-old daughter, their dogs, and himself in Wisconsin in August.

“Nobody in the media has, to my knowledge, had the courage to report what the drugs were, nor have they interviewed the physician or his clinic to find out the rationale for prescribing drugs that have common violence-inducing effects (with black box warnings stating that in the prescribing information),” he writes. “Therefore nothing has been learned from this important teachable moment, probably because revealing the common reality of prescription drug-induced violence would be economically harmful for the sacred cows of Big Pharma and Big Medicine.”

Sen. Jim Webb, D-Va., called the fact that one of every six troops are now on psychoactive drugs “pretty astounding and also very troubling,” in Senate hearings this year.

Retired Col. Bart Billings, a former Army psychologist who has also testified before Congress, says, “I feel flat-out that psychiatrists are directly responsible for deaths in our military, for some of these suicides,” in a March Marine Times article. “I think it’s criminal, what they are doing.”

Even Katie Bagosy, the wife of Marine Sgt. Tom Bagosy, who took his own life in May, indicts the Neurontin medication he was prescribed for his downfall.

“He told me, ‘It all started to get worse when I got on this medication.’ Looking back, that was the beginning of the end,” she says in an article called “A Prescription for Tragedy” in the current National Journal.

http://www.theepochtimes.com/n2/content/view/45181/

« Return to news items


Share

Prescription for prestige—Drug firms’ speaking fees flow to Harvard doctors; concerns about influence prompt new restrictions

Tuesday, October 19th, 2010

The  Boston Globe,  October 19, 2010

Liz Kowalczyk

The Harvard brand, unrivaled in education, is also prized by the pharmaceutical industry as a powerful tool in promoting drugs. Its allure is evident in a new analysis of all publicly reported industry payments to physicians.

Doctors and researchers affiliated with Harvard Medical School collected 45 percent of the $6.3 million given to Massachusetts doctors in 2009 and 2010 by seven pharmaceutical companies that disclosed their payments for parts of those years. The money was mostly for talking to other physicians about the companies’ drugs and the diseases they treat, but also for consulting on research and marketing.

“Companies value the cachet that comes with the name of a prestigious institution,’’ said Dr. Paul Appelbaum, director of the Division of Law, Ethics and Psychiatry at Columbia University College of Physicians and Surgeons. “Even though the institutions themselves are not in any way endorsing the presentations, the aura carries over.’’

The proportion of money going to Harvard doctors underscores why the medical school and its affiliated hospitals, concerned that certain speaking fees can compromise the independence of doctors, are clamping down on such payments.

It is not clear yet whether these restrictions are slowing payments to Harvard doctors, because the data reported publicly are incomplete. But one company, Eli Lilly, gave 50 percent of its payments in 2009 to Harvard doctors and just 33 percent during the first three months of this year.

Many hospitals and medical schools continue to permit doctors to participate in company speakers bureaus, and even at medical centers that largely ban the practice, the analysis — by ProPublica, a nonprofit, online investigative reporting organization, and the Globe — found spotty enforcement.

Consulting with industry to develop new treatments is considered part of an academic physician’s role. But participating in speakers bureaus, while legal, is controversial. Bureau speakers typically show groups of doctors company-created or approved slide presentations about specific drugs or diseases treated by a company’s products. Many of these talks, often held at fancy restaurants, have been moved out of state, doctors said, since last year, when Massachusetts banned doctors from eating the free dinners.

Pharmaceutical companies defend speakers bureaus as an important tool for educating doctors and say industry naturally relies on physicians from top academic medical centers because their peers look up to them.

While some doctors who gave speeches once or twice during 2009 and 2010 earned $2,000 to $3,000, more than two dozen Massachusetts psychiatrists, endocrinologists, and other specialists who gave frequent talks brought in $40,000 to $100,000 and, in a few cases, more. Dr. Lawrence DuBuske, an allergy specialist, earned the most: $219,775. The Globe reported earlier this year that he resigned from Brigham and Women’s Hospital largely because of its new speaking ban.

Partners HealthCare, which includes the Brigham and Massachusetts General and McLean hospitals, halted their doctors’ promotional speaking appearances in January because of concern that they could be perceived as company salespeople and were helping to drive up use of expensive drugs.

Dr. Brent Forester, a geriatric psychiatrist at McLean, was one of the Massachusetts physicians paid the most last year, when he made $73,100 for giving nearly 40 talks for Eli Lilly to colleagues about the antipsychotic Zyprexa and the antidepressant Cymbalta over dinners in restaurants and in doctors offices. He has resigned from speakers bureaus to comply with the new rules, but said he “never felt like a spokesperson for the company at all.’’

“It was an opportunity to educate primary-care doctors about the treatment of psychiatric conditions,’’ Forester said.

Christopher Clark, who oversees compliance for Partners, said his staff searched drug company websites and identified 31 of its physicians who had been hired for speakers bureaus. All but two agreed to resign from the bureaus.

Harvard Medical School itself is also prohibiting participation in speakers bureaus, effective early next year. Consulting payments will still be allowed, with certain restrictions, but will have to be disclosed to Harvard, which has been under pressure from Senator Charles Grassley of Iowa to better monitor its faculty’s relationships with industry.

“We must ensure the integrity and objectivity of all our activities,’’ said Gretchen Brodnicki, the medical school’s dean for faculty research and integrity, who added that the Harvard faculty is huge, about 24 percent of the state’s doctors.

The data on physician payments was compiled from the websites of Eli Lilly, Pfizer, AstraZeneca, GlaxoSmithKline, Merck & Co., Cephalon, and the Johnson & Johnson companies by ProPublica and analyzed for Massachusetts by the Globe.

Companies reported paying about 470 Massachusetts doctors, about 200 of them Harvard faculty, a small percentage of the physicians statewide and of those affiliated with the university.

Most drug companies, however, have not publicly reported payments. The ones that have posted the information report different types of payments for different time periods, so it is not possible to draw definitive conclusions about how many doctors received payments and how much individual doctors earned.

Read the rest of this article here:  http://www.boston.com/news/health/articles/2010/10/19/mass_doctors_earn_drug_firms_dollars/?page=full

« Return to news items


Share

Senator Grassley Investigates WebMD Links to Eli Lilly & WebMD’s ad for people to undergo a Lilly “depression screening”

Wednesday, March 17th, 2010

Epoch Times
By Martha Rosenberg
March 16, 2010

It is not too hard to find evidence of links between WebMD and drug giant Eli Lilly.

A 2002 article on the gigantic medical site about pain and depression says “Lilly is a WebMD Partner,” and an advertising award in 2004 went to the FCB “client” Eli Lilly & Co./WebMD—not clients.

Banner and skyscraper ads for Lilly’s blockbuster antidepressant Cymbalta on WebMD’s home page never seemed to yield to other advertisers in 2009, and the Washington Post reported Lilly and WebMD to be partners in 2000.

Now Sen. Charles Grassley (R-Iowa), ranking Republican on the Senate Finance Committee, is investigating financial ties between Lilly and WebMD Health Corp. because of a WebMD TV ad exhorting people to undergo a Lilly depression screening.

You can joke about the need to tell people they are depressed—do people need to be told they have a headache—but pharma’s screening ruse to recruit new patient pools for the volatile drugs among teens, adolescents, and new mothers is not funny.

Three thousand five hundred news articles about antidepressants linked to violence appear on the Web site SSRIstories.com, including 700 murders, 200 murder-suicides, 51 school shooting incidents, and 54 postpartum depression cases since 1989.

Read entire article:  http://www.theepochtimes.com/n2/content/view/31511/

« Return to news items


Share

Congressional Hearings Held On Antidepressant-Induced Suicide In The Military

Wednesday, March 3rd, 2010

The Huffington Post
By Peter Breggin
March 3, 2010

On February 24, 2010 the Veterans’ Affairs Committee of the U. S. House of Representatives chaired by Bob Filner (D-CA) held hearings on “Exploring the Relationship Between Medication and Veteran Suicide.” Military suicides have risen rapidly in recent years at the same time that the prescription of antidepressants and other psychiatric drugs has escalated. The hearing focused on the dangers of the newer antidepressants like Prozac, Paxil, Zoloft, Celexa, Lexapro, Cymbalta, and Effexor.

Starting in the early 1990s, I was the first psychiatrist to write and speak extensively about the newer antidepressants causing suicide, violence, and mania. It was gratifying when Rep. Filner decided to hold the hearings after reading my new book, Medication Madness: The Role of Psychiatric Drugs in Cases of Violence, Suicide and Crime (2008) and called me as his lead witness. I presented scientific evidence that antidepressants cause suicide, violence and mania. I also emphasized the profound danger of prescribing drugs that cause impulsivity, hostility and suicidality to heavily armed young men and women under stress on active military duty. I recommended that the armed services curtail the use of these drugs and rely instead on psychotherapeutic and educational processes that have already proved effective. I also called for additional research in the military and the VA concerning suicide and violence caused by antidepressants.

There is scant evidence for the effectiveness of antidepressants, and overwhelming evidence for their harmfulness. The military is already moving toward the implementation of better educational programs to help active duty soldiers handle stress. These educational programs, and counseling, need to replace the use of psychiatric drugs.

Read entire article:  http://www.huffingtonpost.com/dr-peter-breggin/congressional-hearings-on_b_480613.html

« Return to news items


Share

Grassley Probes WebMd’s Ties To Eli Lilly for running TV ad encouraging depression screening—sponsored by Eli Lilly

Saturday, February 20th, 2010

Pharmalot
By Ed Silverman
February 19, 2010

Grassley, who is the ranking Republican on the US Senate Finance Committee, is investigating the relationship between WebMD and drugmakers after learning the web site is running a TV ad that encourage people to take a depression-screening test sponsored by Eli Lilly, which sells Cymbalta.

So he wants WebMD, which lots of folks visit for medical info, to disclose its ties to the industry, in general, because the Lilly sponsorship raises questions about WebMD’s “independence,” according to this Feb. 18 letter to WebMD exec Wayne Gattinella. The ad encourages people to visit WebMD’s site to take a depression-screening test.

Read entire article:  http://www.pharmalot.com/2010/02/grassley-probes-webmd-ties-to-eli-lilly/

« Return to news items


Share

Before you take that antidepressant, visit website feauturing 3,500 crimes/suicides related to antidepressant use

Monday, January 4th, 2010

Martha Rosenberg
OpEdNews.com
January 3, 2010

With our national love of drugs, sex, celebrities and violence you’d think SSRIstories.com would be more popular.

The 12-year-old web site lists 3,500 crime related news reports linked to the use of SSRI antidepressants with celebrities like Wynona Ryder, Heath Ledger, Brittany Murphy, Anna Nicole Smith, Heather Locklear, Glen Campbell, Carrie Fisher, Sharon Osbourne, Phil Hartman, Princess Di’s driver, Patrick Swayze’s Sister, O.J. Simpson and the Crown Prince of Nepal generously sprinkled in.

You can search and sort stories by drug–Lexapro, Celexa, Luvox, Prozac, Zoloft and Paxil and the related Effexor and Cymbalta–date, location, type of violence and the articles about school shootings, famous cases and legal cases won on SSRI defenses are color coded.

You don’t even have to read the whole article.

SSRIstories founder and manager Betty Henderson pulls out and boldfaces the story’s drug-related citation like Lynyrd Skynyrd harmonicist Mike Caruso’s remark that, “the doctor put me on Cymbalta. That turned me manic,” and Oklahoma murder suspect Ronson Bush’s remark, “I killed my friend when I took these. I’m not going to take them,” when offered SSRIs at the Grady County Jail.

Read entire article: http://www.opednews.com/articles/Before-You-Take-That-Antid-by-Martha-Rosenberg-100103-313.html

« Return to news items


Share

Pharma spends billions marketing to doctors; Eli Lilly paid $22 million in first 3 months of the year

Friday, August 28th, 2009

Kris Hundley
St. Petersburg Times
August 30, 2009

There are lots of reasons why your doctor might switch your prescription to a Lilly drug.

One of them might be found in a new online database that lists how much Eli Lilly & Co. paid physicians for their expertise during the first quarter of 2009.

For the first time, Floridians can see if their doctors juggled patient appointments with speaking gigs for the maker of popular drugs like Cymbalta, Zyprexa and Cialis.

Drug companies spend billions on marketing to doctors because it works: Targeted doctors prescribe more of the company’s products.

Lilly was forced to disclose its physician pay data, which it calls a “faculty registry,” as part of a $1.4-billion settlement with the federal government earlier this year.

Read entire article: http://www.tampabay.com/news/health/medicine/drug-makers-willing-to-pay-to-get-doctors-approval/1031817

« Return to news items


Share